The Duchenne muscular dystrophy (DMD) treatment landscape continues to evolve, with promising therapies emerging from new insights into disease biology. This activity explores the role of aberrant histone deacetylase (HDAC) activity in DMD pathophysiology, including its impact on inflammation, muscle degeneration, adipogenesis, and fibrosis. You’ll review the latest clinical trial data and real-world evidence for novel therapies and understand where they may fit within complex, existing treatment regimens. Through practical case scenarios, the program highlights how to integrate new approaches into polypharmacy strategies. Stay ahead of the science and get ready to apply it.
=